Brokerages Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Target Price at $91.71

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have received a consensus recommendation of “Moderate Buy” from the fourteen analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $92.79.

Several analysts have issued reports on the company. Piper Sandler dropped their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a report on Monday, March 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Wedbush restated a “neutral” rating and set a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday, January 13th. Wells Fargo & Company boosted their target price on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Finally, HC Wainwright restated a “buy” rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 1,785 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the transaction, the chief financial officer now owns 106,169 shares of the company’s stock, valued at approximately $4,289,227.60. This represents a 1.65 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Theodore Alan Huizenga sold 967 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the completion of the transaction, the chief accounting officer now directly owns 50,265 shares of the company’s stock, valued at approximately $2,116,156.50. This represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 136,370 shares of company stock worth $5,751,499. Insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC increased its position in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 493 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in Ultragenyx Pharmaceutical during the 4th quarter worth $35,000. Human Investing LLC purchased a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth about $42,000. True Wealth Design LLC acquired a new stake in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $43,000. Finally, Van ECK Associates Corp boosted its stake in shares of Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 273 shares during the period. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Trading Up 2.4 %

Shares of NASDAQ RARE opened at $38.89 on Tuesday. The stock has a market cap of $3.60 billion, a PE ratio of -6.13 and a beta of 0.67. Ultragenyx Pharmaceutical has a 12-month low of $36.71 and a 12-month high of $60.37. The company has a 50-day moving average of $41.68 and a 200 day moving average of $47.03.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.